These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8157961

  • 1. Acute rejection of marrow grafts in mice. Dependence on and independence of functional TCR in the rejection process.
    Takeda K, Moore MW, Dennert G.
    J Immunol; 1994 May 01; 152(9):4407-16. PubMed ID: 8157961
    [Abstract] [Full Text] [Related]

  • 2. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection.
    Kikly K, Dennert G.
    J Immunol; 1992 Dec 01; 149(11):3489-94. PubMed ID: 1431119
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C, Höglund P, Sentman CL, Carbone E, Ljunggren HG, Koller B, Kärre K.
    Eur J Immunol; 1995 May 01; 25(5):1286-91. PubMed ID: 7774631
    [Abstract] [Full Text] [Related]

  • 4. Evidence for extrathymic development of TNK cells. NK1+ CD3+ cells responsible for acute marrow graft rejection are present in thymus-deficient mice.
    Kikly K, Dennert G.
    J Immunol; 1992 Jul 15; 149(2):403-12. PubMed ID: 1385604
    [Abstract] [Full Text] [Related]

  • 5. Hybrid and allogeneic resistance to T cell grafts mediated by murine NK and CD8+ T cells.
    Davenport C, Haile A, Kumar V, Bennett M.
    J Immunol; 1995 Mar 15; 154(6):2568-77. PubMed ID: 7876533
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R, Waldenström M, Höglund P, Klein G, Kärre K, Ljunggren HG.
    Cancer Res; 1995 May 01; 55(9):1911-6. PubMed ID: 7728758
    [Abstract] [Full Text] [Related]

  • 9. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.
    Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D.
    Nature; 1991 Jan 24; 349(6307):329-31. PubMed ID: 1987491
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A new T-cell receptor transgenic model of the CD4+ direct pathway: level of priming determines acute versus chronic rejection.
    Brennan TV, Hoang V, Garrod KR, Liu FC, Hayden T, Kim J, Kang SM.
    Transplantation; 2008 Jan 27; 85(2):247-55. PubMed ID: 18212630
    [Abstract] [Full Text] [Related]

  • 12. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
    Dennert G, Anderson CG, Warner J.
    J Immunol; 1986 Jun 01; 136(11):3981-6. PubMed ID: 3517162
    [Abstract] [Full Text] [Related]

  • 13. Maturation and function of mouse T-cells with a transgenic TCR positively selected by highly disparate xenogeneic porcine MHC.
    Zhao Y, Rodriguez-Barbosa JI, Zhao G, Shaffer J, Arn JS, Sykes M.
    Cell Mol Biol (Noisy-le-grand); 2001 Feb 01; 47(1):217-28. PubMed ID: 11292257
    [Abstract] [Full Text] [Related]

  • 14. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow.
    Nakamura H, Gress RE.
    Transplantation; 1990 Feb 01; 49(2):453-8. PubMed ID: 2305471
    [Abstract] [Full Text] [Related]

  • 15. Demonstration of MHC class I-specific cytolytic activity in IL-2-activated NK1+CD3+ cells and evidence of usage of T and NK cell receptors.
    Takeda K, Dennert G.
    Transplantation; 1994 Aug 27; 58(4):496-504. PubMed ID: 8073519
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets.
    Raziuddin A, Longo DL, Mason L, Ortaldo JR, Bennett M, Murphy WJ.
    J Immunol; 1998 Jan 01; 160(1):87-94. PubMed ID: 9551959
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow allograft rejection mediated by a novel murine NK receptor, NKG2I.
    Koike J, Wakao H, Ishizuka Y, Sato TA, Hamaoki M, Seino K, Koseki H, Nakayama T, Taniguchi M.
    J Exp Med; 2004 Jan 05; 199(1):137-44. PubMed ID: 14707119
    [Abstract] [Full Text] [Related]

  • 18. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
    Kapessidou Y, Habran C, Buonocore S, Flamand V, Barvais L, Goldman M, Braun MY.
    Transplantation; 2006 Aug 27; 82(4):582-91. PubMed ID: 16958183
    [Abstract] [Full Text] [Related]

  • 19. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM.
    J Immunol; 1997 Nov 15; 159(10):4665-75. PubMed ID: 9366389
    [Abstract] [Full Text] [Related]

  • 20. Effector cell expression of NK1.1, a murine natural killer cell-specific molecule, and ability of mice to reject bone marrow allografts.
    Sentman CL, Kumar V, Koo G, Bennett M.
    J Immunol; 1989 Mar 15; 142(6):1847-53. PubMed ID: 2646375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.